Safety and Efficacy Study for the Treatment of BPH (Enlarged Prostate) (REZUM)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01912339|
Recruitment Status : Completed
First Posted : July 31, 2013
Results First Posted : May 15, 2017
Last Update Posted : February 2, 2018
|Condition or disease||Intervention/treatment||Phase|
|Benign Prostatic Hyperplasia Lower Urinary Tract Symptom||Device: Rezum System Procedure: Rigid Cystoscopy||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||197 participants|
|Intervention Model:||Crossover Assignment|
|Official Title:||Minimally Invasive Prostatic Vapor Ablation - Multicenter, Controlled Study for the Treatment of BPH (Rezūm II)|
|Study Start Date :||July 2013|
|Actual Primary Completion Date :||March 2015|
|Actual Study Completion Date :||October 17, 2016|
Treatment: Rezūm System
Device: Rezum System
The Rezūm System uses sterile water vapor (steam) to treat BPH by delivering targeted, controlled doses of stored thermal energy directly to the transition zone of the prostate gland.
A narrow sheath, similar in shape and size to a cystoscope, is inserted transurethrally and positioned within the prostatic urethra between the bladder neck and the verumontanum.
A thin needle is deployed through the urethra into the transition zone, and a very short (8-10 second) treatment of water vapor is delivered directly into the hyperplastic tissue and immediately disperses through the tissue interstices.
Upon contact with the tissue, the vapor condenses, or phase shifts, into its liquid state, releasing the stored thermal energy contained within the vapor. This thermal energy is released directly against the walls of the tissue cells within the treatment zone, gently and immediately denaturing the cell membranes, thereby causing instantaneous cell death.
Control: Rigid Cystoscopy
Procedure: Rigid Cystoscopy
Endoscopy of the urinary bladder via the urethra.
Other Name: Cystoscopy
- Efficacy: Change From Baseline in the International Prostate Symptom Score (IPSS) at 3 Month Follow-Up [ Time Frame: 3 Month Follow-up Visit ]Comparison of the change in BPH symptoms as measured by IPSS change between the Treatment and Control arm at 3 months post-treatment. The IPSS is a well-validated, highly reliable and responsive American Urological Association symptom score (AUASS) assessment to identify the severity of BPH Symptoms. The first seven questions of the IPSS Questionnaire address frequency, nocturia, weak urinary stream, hesitancy, intermittence, incomplete emptying and urgency each on a scale of 0 to 5. The total score, summed across the seven items measured, ranges from 0 (no symptoms) to 35 (most severe symptoms).
- Safety: Device Related Serious Complications [ Time Frame: 3 Months ]
This safety endpoint will be to demonstrate that the composite observed rate of post-procedure device related serious complications in the Treatment Arm are is less than or equal to 12% at 3 months.
Composite device related serious complications for this endpoint are 1) De Novo (new) severe urinary retention lasting more than 21 consecutive days post treatment, 2) Device related formation of fistula between the rectum and urethra, and 3) device perforation of the rectum or GI tract. Twelve percent was a pre-specified performance goal for the safety endpoint.
- Responders at 3 Months [ Time Frame: 3 Months ]Number of subjects with a greater than or equal to 30% improvement (reduction) in the International Prostate Symptom score (IPSS) at 3 months compared to baseline.
- Responders at 6 Months [ Time Frame: 6 Months ]Number of subjects with a greater than or equal to 30% improvement (reduction) in the International Prostate Symptom score (IPSS) at 6 months compared to baseline.
- Responders at 12 Months [ Time Frame: 12 Months ]Number of subjects with a greater than or equal to 30% improvement (reduction) in the International Prostate Symptom score (IPSS) at 12 months compared to baseline.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01912339
|United States, Arizona|
|Arizona Institute of Urology|
|Tucson, Arizona, United States, 85704|
|United States, Colorado|
|Urology Associates of Denver|
|Denver, Colorado, United States, 80113|
|United States, Florida|
|South Florida Medical Research|
|Aventura, Florida, United States, 33180|
|United States, Illinois|
|Southern Illinois University|
|Springfield, Illinois, United States, 62794|
|United States, Maryland|
|Towson, Maryland, United States, 21204|
|United States, Minnesota|
|Rochester, Minnesota, United States, 55905|
|Woodbury, Minnesota, United States, 55125|
|United States, New York|
|Manhattan Medical Research|
|New York, New York, United States, 10016|
|United States, Ohio|
|The Urology Group|
|Cincinnati, Ohio, United States, 45212|
|Cleveland, Ohio, United States, 44195|
|United States, South Carolina|
|Carolina Urologic Research Center|
|Myrtle Beach, South Carolina, United States, 29572|
|United States, Texas|
|Carrollton, Texas, United States, 75010|
|Dallas, Texas, United States, 75390|
|Urology of San Antonio|
|San Antonio, Texas, United States, 78229|
|United States, Utah|
|Jean Brown Research|
|Salt Lake City, Utah, United States, 84124|
|Principal Investigator:||Claus Roehrborn, MD||UT Southwestern|
|Principal Investigator:||Kevin McVary, MD||Southern Illinois University|